CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study
Open Access
- 27 September 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Hereditas
- Vol. 159 (1), 1-15
- https://doi.org/10.1186/s41065-022-00251-y
Abstract
C-C chemokine receptor 5 (CCR5) has recently been recognized as an underlying therapeutic target for various malignancies. However, the association of CCR5 with prognosis in the head and neck squamous cell carcinoma (HNSC) patients and tumor-infiltrating lymphocytes (TILs) is unclear. In the current experiment, methods such as the Tumor Immune Estimation Resource Analysis (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN, and Kaplan-Meier plotter Analysis were used to comprehensively evaluate the expression of CCR5 in human various malignancies and the clinical prognosis in HNSC patients. Subsequently, we used the TIMER database and the TISIDB platform to investigate the correlation between CCR5 expression levels and immune cell infiltration in the HNSC tumor microenvironment. Furthermore, immunomodulatory and chemokine profiling were performed using the TISIDB platform to analyse the correlation between CCR5 expression levels and immunomodulation in HNSC patients. We found that CCR5 expression in HNSC tumor tissues was significantly upregulated than in normal tissues. In HNSC, patients with high CCR5 expression levels had worse overall survival (OS, HR = 0.59, p = 0.00015) and worse recurrence-free survival (RFS, HR = 3.27, p = 0.00098). Upregulation of CCR5 expression is closely associated with immunomodulators, chemokines, and infiltrating levels of CD4+ T cells, neutrophils, macrophages, and myeloid dendritic cells. Furthermore, upregulated CCR5 was significantly associated with different immune markers in the immune cell subsets of HNSC. High expression of CCR5 plays an important prognostic role in HNSC patients and may serve as a prognostic biomarker correlated with immune infiltration, and further studies are still needed to investigate therapeutic targeting HNSC patients in the future.Keywords
Funding Information
- the science and technology plan of National Natural Science Foundation of China (No. 82060393)
- Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders (No. 19-xkjs-05)
- Guilin Science and Technology Plan Project (No. 20210227-8-7)
- Guangxi Medical and Health Appropriate Technology Development and Promotion Project (No. S2020106)
- The project of improving the basic scientific research ability of young and middle-aged teachers in Guangxi universities (No. 2022KY0502)
- Guangxi Natural Science Foundation (No. 2022GXNSFAA103002)
This publication has 26 references indexed in Scilit:
- Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-OncologyCancer Research, 2019
- TISIDB: an integrated repository portal for tumor–immune system interactionsBioinformatics, 2019
- Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5Cell Death & Disease, 2019
- Clinicopathological significance of chemokine receptor (CCR1, CCR3, CCR4, CCR5, CCR7 and CXCR4) expression in head and neck squamous cell carcinomasJournal of Oral Pathology & Medicine, 2018
- CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cellsScientific Reports, 2018
- In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virusScientific Reports, 2018
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Research, 2017
- Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and TreatmentMayo Clinic Proceedings, 2016
- CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer CellsCancer Research, 2012
- Chemokine receptor CCR5: insights into structure, function, and regulationCellular Signalling, 2004